Skip to main content
Case Study

Science 37 Utilizes Flexibility of the Metasite Model in Study of Rare Disease

A biotech company approached Science 37 to develop a virtualized process to evaluate patients who may be eligible for an interventional study with a novel gene therapy program for a very rare, life-altering disease, known as Classic Congenital Adrenal Hyperplasia (CAH) without the need to open countless brick-and-mortar sites to recruit these patients.


Learn how Science 37 Metasite delivered:

  • 100+ preliminary eligible patients
  • Nearly 50 total consented
  • Mobile nursing supporting patients at home for blood collection
  • 6+ months of monitoring and engagement